XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: Dec 6, 2018
XyloCor Therapeutics Raises $17 Million in Series A Financing to Advance Gene Therapy Portfolio in Cardiovascular Disease
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.